PPD nabs Bioclinica clinical research site business

PPD
The CRO said this will boost its geogrpahic reach (PPD)

As part of its ambition to become the world’s largest patient access and site conduct organization, CRO PPD has snapped up Bioclinica’s research site biz.

This will be enveloped into PPD’s Accelerated Enrollment Solutions (AES), one of its business units, boosting the company's global footprint as it reaches into new areas including China, Latin America and western Europe.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

The deal also includes those research sites from the merger of Bioclinica and CCBR-SYNARC back in 2014, bolsters the AES unit's presence in the U.S. and and adds four dedicated sites in Florida, the CRO said in a statement.

“With these new assets operating on five continents, AES is a place where customers can receive 50-100% of their entire trial enrollment from one accountable solution, delivered by research locations that operate uniformly across the globe,” said Roger Smith, senior vice president and general manager of AES.

“We can now address two major impediments to meaningful improvement in site selection and patient enrollmen—namely, investigator site capacity and the ability to predictably bring new patients into research with our data modeling and analytical capabilities.

“Our approach can reduce customers’ reliance on patient availability from investigator databases and practices. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to AES to be part of our solution-oriented culture and help advance drug development to improve patients’ lives.”

This comes several weeks after PPD penned a collaboration with Harbour BioMed to help develop new meds for cancer and immunology.

RELATED: Bioclinica wants to move the needle in NASH

David Herron, president and CEO of Bioclinica, added: “We believe PPD’s AES business unit is an outstanding strategic fit for the global site business. Both organizations have long been committed to clinical research and together they will provide excellent value for sponsors and CROs.

“This transaction enables AES to take patient access and site conduct to a new level, while enabling Bioclinica to accelerate its delivery of exceptional services in medical imaging, cardiovascular safety, eClinical and trial software, and drug safety solutions.”

As is becoming increasingly common in the biopharma service world, financial details of the deal were not disclosed.

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.